VTVT

MKT CAP:$86M

vTv Therapeutics Inc.

Market Cap

$86M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$34.85-$4.75 (-11.99%)

Apr 23, 2026

Company Details

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective gluc...

CEO

Paul J. Sekhri

IPO Date

Jul 30, 2015

Website

www.vtvtherapeutics.com

Key Metrics TTM

Revenue

$993.0K

+10933.3% YoY

Net Income

-$24M

EPS (Diluted)

-$3.46

Free Cash Flow

-$27M

Revenue / Share

$0.12

Gross Margin

99.0%

Operating Margin

-2930.8%

Net Margin

-2450.7%

FCF Margin

-2682.1%

P/S

86.6x

P/E

—

Earnings Reports

Q4 2025

Mar 10, 2026

-$24.0K-241.2%EPS -$0.58

Q3 2025

Nov 6, 2025

$0EPS -$1.08

Q4 2024

Mar 20, 2025

$17.0KEPS -$0.63

Q1 2024

May 9, 2024

$1MEPS -$1.17

FY 2023

Mar 13, 2024

$0-100.0%EPS -$9.71

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$9.0K	-$2M	-$5M
Q3 21	$3M	$618.0K	-$2M
Q3 22	$0	$0	-$6M
Q4 22	$9.0K	$9.0K	-$6M
Q1 23	$0	$0	-$7M
Q3 23	$0	$0	-$5M
Q4 23	$0	$0	-$5M
Q1 24	$1M	$1M	-$6M
Q4 24	$17.0K	-$5.0K	-$5M
Q3 25	$0	$0	-$11M
Q4 25	-$24.0K	-$12.0K	-$8M

Valuation

Quarter	P/S	P/E
Q2 21	—	—
Q3 21	—	—
Q3 22	—	—
Q4 22	28.5x	—
Q1 23	28.6x	—
Q3 23	9560.1x	—
Q4 23	9560.1x	—
Q1 24	86.0x	—
Q4 24	84.6x	—
Q3 25	84.6x	—
Q4 25	86.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	-$4M	-$4M
Q3 21	-$3M	-$3M
Q3 22	-$8M	-$8M
Q4 22	-$7M	-$7M
Q1 23	-$5M	-$5M
Q3 23	-$5M	-$5M
Q4 23	-$3M	-$3M
Q1 24	-$7M	-$7M
Q4 24	-$5M	-$5M
Q3 25	-$5M	-$5M
Q4 25	-$9M	-$9M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-100.0%	+58.7%
Q3 23	-100.0%	+16.6%
Q4 23	—	-17.3%
Q1 24	+11011.1%	+4.3%
Q4 24	—	-33.9%
Q3 25	—	+99.3%
Q4 25	—	+67.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q3 22	$0	—
Q4 22	$0	0.0%
Q1 23	$0	—
Q3 23	$433.0K	—
Q4 23	$403.0K	—
Q1 24	$220.0K	22.0%
Q4 24	$825.0K	4852.9%
Q3 25	$0	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A
Q2 21	$2M	$2M
Q3 21	$2M	$2M
Q3 22	$3M	$3M
Q4 22	$4M	$2M
Q1 23	$4M	$3M
Q3 23	$3M	$3M
Q4 23	$2M	$3M
Q1 24	$3M	$4M
Q4 24	$2M	$3M
Q3 25	$7M	$4M
Q4 25	$4M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$12M	$0	$12M
Q2 22	$18M	$0	$18M
Q3 22	$15M	$0	$15M
Q4 22	$12M	$0	$12M
Q1 23	$19M	$0	$19M
Q2 23	$13M	$0	$13M
Q3 23	$8M	$0	$8M
Q4 23	$9M	$0	$9M
Q1 24	$52M	$0	$52M
Q2 24	$46M	$0	$46M
Q3 24	$42M	$0	$42M
Q4 24	$37M	$0	$37M
Q1 25	$31M	$0	$31M
Q2 25	$26M	$0	$26M
Q3 25	$99M	$0	$99M
Q4 25	$89M	$0	$89M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	1M	—	—
Q3 21	2M	+4.2%	—
Q3 22	2M	+31.8%	—
Q4 22	2M	+1.2%	—
Q1 23	2M	0.0%	+39.0%
Q3 23	2M	0.0%	+33.4%
Q4 23	2M	+2.4%	+3.6%
Q1 24	4M	+98.6%	+103.3%
Q4 24	6M	+39.3%	+183.3%
Q3 25	8M	+39.6%	+295.5%
Q4 25	8M	+4.6%	+304.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	$360	25
Q3 21	$120.0K	25
Q3 22	$0	9
Q4 22	$692	13
Q1 23	$0	13
Q3 23	$0	13
Q4 23	$0	16
Q1 24	$62.5K	16
Q4 24	$739	23
Q3 25	$0	23
Q4 25	-$923	26

Revenue / Employee